The FDA is reviewing Boston Scientific's defibrillator leads after reports of rising shock impedance and 16 related deaths.

U.S. health officials have issued warnings on two separate Boston Scientific heart devices recently linked to injuries and ...

While neither warning is classified as a recall, the FDA has provided additional information for the two products. Boston Scientific told customers that its Endotak Reliance defibrillation leads with ...

Boston Scientific has updated the instructions for use for products deployed in the implantation of its Watchman heart device ...

The FDA has issued an alert regarding a safety concern with certain Boston Scientific defibrillator leads used in implantable cardioverter defibrillators. The affected models include Endotak Reliance, ...

Boston Scientific Corporation (NYSE:BSX) is one of the best high-volume stocks to invest in. On August 6, the FDA announced ...

Boston Scientific Corporation (NYSE:BSX) is one of the best stocks to invest in for beginners. In a report released on August ...

Boston Scientific has launched Endura Weight Loss Solutions, alongside survey findings showing that many U.S. women are ...

Boston Scientific’s revenues rose from $18.4 billion in 2019 to $20.2 billion in 2022, driven by an uptick in total procedures after a decline during the pandemic period.

Now, although Boston Scientific’s revenue growth of 12% in the last quarter was better than 8.6% growth for Stryker, due to a sharp rebound in procedure volume, things are very different if we ...

Boston Scientific Corp. BSX -0.28% agreed to pay Johnson & Johnson JNJ 6.19% $600 million to settle a long-running lawsuit related to the 2006 acquisition of heart-device maker Guidant Corp. for ...

Boston Scientific could easily lose $100 million in sales by canning the reps, but, “We are going to run the company properly, and if we’re a somewhat smaller company short term or long term ...